A significant proportion of elderly patients develop hormone-dependent luminal-B tumours associated with aggressive characteristics : Geriatric oncologyDURBECQ, V; AMEYE, L; LARSIMONT, D et al.Critical reviews in oncology/hematology. 2008, Vol 67, Num 1, pp 80-92, issn 1040-8428, 13 p.Article

Evaluation of the histological size of the sentinel lymph node metastases using RT―PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancerVEYS, I; MAJJAJ, S; SALGADO, R et al.Breast cancer research and treatment. 2010, Vol 124, Num 3, pp 599-605, issn 0167-6806, 7 p.Article

HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelDI LEO, A; CHAN, S; KOREC, S et al.Breast cancer research and treatment. 2004, Vol 86, Num 3, pp 197-206, issn 0167-6806, 10 p.Article

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancerAZAMBUJA, E; DURBECQ, V; ROSA, D. D et al.Annals of oncology. 2008, Vol 19, Num 2, pp 223-232, issn 0923-7534, 10 p.Article

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancerCARDOSO, F; DURBECQ, V; DI LEO, A et al.International journal of oncology. 2004, Vol 24, Num 1, pp 201-209, issn 1019-6439, 9 p.Article

Correlation between topoisomerase-IIα gene amplification and protein expression in HER-2 amplified breast cancerDURBECQ, V; DESMEDT, C; LARSIMONT, D et al.International journal of oncology. 2004, Vol 25, Num 5, pp 1473-1479, issn 1019-6439, 7 p.Article

Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12 155 patientsDE AZAMBUJA, E; CARDOSO, F; DE CASTRO JR, G et al.British journal of cancer. 2007, Vol 96, Num 10, pp 1504-1513, issn 0007-0920, 10 p.Article

P-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trialDI LEO, A; TANNER, M; PICCART, M. J et al.Annals of oncology. 2007, Vol 18, Num 6, pp 997-1003, issn 0923-7534, 7 p.Article

Comparison of topoisomerase-IIα gene status between primary breast cancer and corresponding distant metastatic sitesDURBECQ, V; DI LEO, A; CARDOSO, F et al.Breast cancer research and treatment. 2003, Vol 77, Num 3, pp 199-204, issn 0167-6806, 6 p.Article